牛牛AI助理已提取核心訊息
EyePoint Pharmaceuticals Inc officer Dario A Paggiarino is set to sell 66,311 shares of common stock on January 23, 2024. The shares to be sold were acquired on the same date through the exercise of stock options, with the securities obtained directly from the issuer. The transaction is a cash exercise, and the aggregate market value of the shares to be sold is approximately $1,590,137.78. This planned sale follows a three-month period where Paggiarino sold a total of 54,996 shares, grossing $1,187,034.19.
EyePoint Pharmaceuticals Inc officer Dario A Paggiarino is set to sell 66,311 shares of common stock on January 23, 2024. The shares to be sold were acquired on the same date through the exercise of stock options, with the securities obtained directly from the issuer. The transaction is a cash exercise, and the aggregate market value of the shares to be sold is approximately $1,590,137.78. This planned sale follows a three-month period where Paggiarino sold a total of 54,996 shares, grossing $1,187,034.19.
EyePoint Pharmicals Inc高管達里奧·帕賈裏諾定於2024年1月23日出售66,311股普通股。待售股票於同日通過行使股票期權收購，證券直接從發行人處獲得。該交易是現金交易，待售股票的總市值約爲1,590,137.78美元。此次計劃出售是在三個月之後進行的，帕賈裏諾共出售了54,996股股票，總收入爲1,187,034.19美元。
EyePoint Pharmicals Inc高管達里奧·帕賈裏諾定於2024年1月23日出售66,311股普通股。待售股票於同日通過行使股票期權收購，證券直接從發行人處獲得。該交易是現金交易，待售股票的總市值約爲1,590,137.78美元。此次計劃出售是在三個月之後進行的，帕賈裏諾共出售了54,996股股票，總收入爲1,187,034.19美元。
有用
沒用